These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19668153)

  • 21. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 22. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
    Chakradhar S; Khamsi R
    Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
    [No Abstract]   [Full Text] [Related]  

  • 23. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 24. Fresh from the biologic pipeline-2009.
    Sheridan C
    Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
    [No Abstract]   [Full Text] [Related]  

  • 25. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
    Kuhrt K; Chace-Ortiz M
    IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 27. 3 New Biologics To Be Worth $14B in Sales by 2019.
    Adams KT
    Manag Care; 2015 May; 24(5):36-7. PubMed ID: 26117964
    [No Abstract]   [Full Text] [Related]  

  • 28. Progress and Hurdles for Follow-on Biologics.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jun; 372(25):2380-2. PubMed ID: 25946143
    [No Abstract]   [Full Text] [Related]  

  • 29. Profit-hungry pharma sees some biotechs as ripe for the picking.
    Willyard C
    Nat Med; 2009 May; 15(5):466. PubMed ID: 19424184
    [No Abstract]   [Full Text] [Related]  

  • 30. Patent Cliffs in the Era of Complex Therapies and Biologics.
    Sabatini MT; Silva M
    Pharmaceut Med; 2020 Aug; 34(4):271-278. PubMed ID: 32772314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall.
    Dorey E
    Nat Biotechnol; 2010 Nov; 28(11):1137-8. PubMed ID: 21057465
    [No Abstract]   [Full Text] [Related]  

  • 32. Cheaper clinical trials: the real solution to the biologic industry's Gordian knot.
    Montas A
    Am J Law Med; 2011; 37(1):172-93. PubMed ID: 21614998
    [No Abstract]   [Full Text] [Related]  

  • 33. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
    Kuhrt K
    IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 35. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent trends in brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
    Rome BN; Lee CC; Kesselheim AS
    Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.